Of all the factors doctors consider when predicting whether Graves' disease will return after medication, only the size of the thyroid gland and the presence of certain antibodies at the end of treatment reliably indicate higher relapse risk—other factors like age or how long the drugs were taken do not.
Claim Context
Among multiple clinical and laboratory variables, only goiter size and persistent TBII positivity at treatment end are independently associated with relapse risk after antithyroid drug therapy for Graves' disease, suggesting other factors like age, sex, or treatment duration have minimal predictive value.
“mientras que del resto de las variables estudiadas (edad, sexo, tamaño del bocio, duración del tratamiento, positividad de los anticuerpos antitiroideos y de los TBII) sólo la positividad de los TBII al final del tratamiento influyó de forma muy significativa (p < 0,05).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether goiter size and TBII positivity are consistently the only significant predictors across diverse populations, or whether other factors (e.g., HLA type, smoking) become significant in subgroups.
A systematic review and meta-analysis of all multivariate regression models from prospective studies evaluating predictors of relapse after antithyroid drug therapy, extracting adjusted hazard ratios for age, sex, goiter size, TBII, treatment duration, and antibody types, with subgroup analysis by region and assay method.
An RCT could test whether adding interventions targeting non-predictive factors (e.g., smoking cessation, vitamin D supplementation) improves remission rates, confirming their lack of impact.
A multicenter RCT of 800 adults with Graves' disease and large goiter/TBII positivity, randomized to standard therapy versus standard therapy plus smoking cessation program and vitamin D supplementation, with primary outcome of sustained remission at 5 years, to test whether modifying non-predictive factors alters outcomes.
A prospective cohort study could validate whether goiter size and TBII remain the only significant predictors in a contemporary population with standardized measurements.
A prospective cohort of 1200 adults with Graves' disease, measuring goiter volume, TBII, TSH receptor antibodies, age, sex, treatment duration, smoking, and iodine intake at diagnosis and treatment end, with multivariable Cox regression to identify independent predictors of relapse over 10 years.
A case-control study could compare the prevalence of other variables between relapsed and remitted patients to confirm their lack of association.
A matched case-control study of 400 patients: 200 with relapse within 5 years and 200 matched controls, comparing baseline age, sex, treatment duration, smoking status, and non-TBII antibody levels, using conditional logistic regression to confirm no significant associations.
A cross-sectional study could estimate the distribution of other variables among patients with relapse, but cannot determine their predictive value over time.
A cross-sectional survey of 600 patients with Graves' disease relapse, measuring age, sex, treatment duration, and antibody status at time of relapse, comparing to a control group of 600 in remission, to assess whether other factors differ.